Cargando…

The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma

OBJECTIVE: This study aimed to study the diagnostic efficacy of positron emission tomography (PET)/magnetic resonance imaging (MRI), computed tomography (CT) and clinical metabolic parameters in predicting the histological classification of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xin, Wu, Jiaojiao, Liang, Jiangtao, Yuan, Changfeng, Shi, Feng, Ding, Zhongxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445186/
https://www.ncbi.nlm.nih.gov/pubmed/36081569
http://dx.doi.org/10.3389/fonc.2022.991102
_version_ 1784783371715477504
author Tang, Xin
Wu, Jiaojiao
Liang, Jiangtao
Yuan, Changfeng
Shi, Feng
Ding, Zhongxiang
author_facet Tang, Xin
Wu, Jiaojiao
Liang, Jiangtao
Yuan, Changfeng
Shi, Feng
Ding, Zhongxiang
author_sort Tang, Xin
collection PubMed
description OBJECTIVE: This study aimed to study the diagnostic efficacy of positron emission tomography (PET)/magnetic resonance imaging (MRI), computed tomography (CT) and clinical metabolic parameters in predicting the histological classification of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC). METHODS: PET/MRI, CT and clinical metabolic data of 80 patients with lung ADC or SCC were retrospectively collected. According to the pathological results from surgery or fiberscopy, the patients were diagnosed with lung ADC (47 cases) or SCC (33 cases). All 80 patients were divided into a training group (64 cases), an internal testing group (8 cases) and an external testing group (8 cases) in the ratio of 8:1:1. Nine models were constructed by integrating features from different modalities. The Gaussian classifier was used to differentiate ADC and SCC. The prediction ability was evaluated using the receiver operating characteristic curve. The area under the curve (AUC) of the models was compared using Delong’s test. Based on the best composite model, a nomogram was established and evaluated with a calibration curve, decision curve and clinical impact curve. RESULTS: The composite model (PET/MRI + CT + Clinical) owned the highest AUC values in the training, internal testing and external testing sets, respectively. In the training set, significant differences in the AUC were found between the composite model and other models except for the PET/MRI + CT model. The calibration curves showed good consistency between the predicted output and actual disease. The decision curve analysis and clinical impact curves demonstrated that the composite model increased the clinical net benefit for predicting lung cancer subtypes. CONCLUSION: The composite prediction model of PET/MRI + CT + Clinical better distinguished ADC from SCC pathological subtypes preoperatively and achieved clinical benefits, thus providing an accurate clinical diagnosis.
format Online
Article
Text
id pubmed-9445186
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94451862022-09-07 The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma Tang, Xin Wu, Jiaojiao Liang, Jiangtao Yuan, Changfeng Shi, Feng Ding, Zhongxiang Front Oncol Oncology OBJECTIVE: This study aimed to study the diagnostic efficacy of positron emission tomography (PET)/magnetic resonance imaging (MRI), computed tomography (CT) and clinical metabolic parameters in predicting the histological classification of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC). METHODS: PET/MRI, CT and clinical metabolic data of 80 patients with lung ADC or SCC were retrospectively collected. According to the pathological results from surgery or fiberscopy, the patients were diagnosed with lung ADC (47 cases) or SCC (33 cases). All 80 patients were divided into a training group (64 cases), an internal testing group (8 cases) and an external testing group (8 cases) in the ratio of 8:1:1. Nine models were constructed by integrating features from different modalities. The Gaussian classifier was used to differentiate ADC and SCC. The prediction ability was evaluated using the receiver operating characteristic curve. The area under the curve (AUC) of the models was compared using Delong’s test. Based on the best composite model, a nomogram was established and evaluated with a calibration curve, decision curve and clinical impact curve. RESULTS: The composite model (PET/MRI + CT + Clinical) owned the highest AUC values in the training, internal testing and external testing sets, respectively. In the training set, significant differences in the AUC were found between the composite model and other models except for the PET/MRI + CT model. The calibration curves showed good consistency between the predicted output and actual disease. The decision curve analysis and clinical impact curves demonstrated that the composite model increased the clinical net benefit for predicting lung cancer subtypes. CONCLUSION: The composite prediction model of PET/MRI + CT + Clinical better distinguished ADC from SCC pathological subtypes preoperatively and achieved clinical benefits, thus providing an accurate clinical diagnosis. Frontiers Media S.A. 2022-08-23 /pmc/articles/PMC9445186/ /pubmed/36081569 http://dx.doi.org/10.3389/fonc.2022.991102 Text en Copyright © 2022 Tang, Wu, Liang, Yuan, Shi and Ding https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tang, Xin
Wu, Jiaojiao
Liang, Jiangtao
Yuan, Changfeng
Shi, Feng
Ding, Zhongxiang
The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma
title The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma
title_full The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma
title_fullStr The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma
title_full_unstemmed The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma
title_short The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma
title_sort value of combined pet/mri, ct and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445186/
https://www.ncbi.nlm.nih.gov/pubmed/36081569
http://dx.doi.org/10.3389/fonc.2022.991102
work_keys_str_mv AT tangxin thevalueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT wujiaojiao thevalueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT liangjiangtao thevalueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT yuanchangfeng thevalueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT shifeng thevalueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT dingzhongxiang thevalueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT tangxin valueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT wujiaojiao valueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT liangjiangtao valueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT yuanchangfeng valueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT shifeng valueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma
AT dingzhongxiang valueofcombinedpetmrictandclinicalmetabolicparametersindifferentiatinglungadenocarcinomafromsquamouscellcarcinoma